{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:06Z","timestamp":1788966066148,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10157-023-02325-1","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T23:46:32Z","timestamp":1675899992000},"page":"427-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"umin000022422","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kota","family":"Kakeshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2325_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1681\/ASN.V133798","volume":"13","author":"CS Wilcox","year":"2002","unstructured":"Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol. 2002;13:798\u2013805.","journal-title":"J Am Soc Nephrol"},{"key":"2325_CR2","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"2325_CR3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","volume":"83","author":"K Kinugawa","year":"2019","unstructured":"Kinugawa K, Sato N, Inomata T, Yasuda M, Shimakawa T, Fukuta Y. Real-world effectiveness and tolerability of tolvaptan in patients with heart failure - final results of the Samsca post-marketing surveillance in heart failure (SMILE) study. Circ J. 2019;83:1520\u20137.","journal-title":"Circ J"},{"key":"2325_CR4","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1536\/ihj.18-119","volume":"59","author":"K Kinugawa","year":"2018","unstructured":"Kinugawa K, Sato N, Inomata T. Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J. 2018;59:1368\u201377.","journal-title":"Int Heart J"},{"key":"2325_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment - Results from the K-STAR study. Circ J. 2017;82:159\u201367.","journal-title":"Circ J."},{"key":"2325_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10157-022-02224-x","volume":"26","author":"S Komiya","year":"2022","unstructured":"Komiya S, Katsumata M, Ozawa M, Haze T, Kawano R, Ohki Y, et al. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial. Clin Exp Nephrol. 2022;26:851\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2325_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/1744-9987.12789","volume":"23","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Hiramatsu E, Watanabe Y, Ito C, Shinjo H, Otsuka Y, et al. Efficacy of long-term treatment with tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure. Ther Apher Dial. 2019;23:319\u201327.","journal-title":"Ther Apher Dial"},{"key":"2325_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1536\/ihj.14-190","volume":"55","author":"E Sato","year":"2014","unstructured":"Sato E, Nakamura T, Amaha M, Nomura M, Matsumura D, Yamagishi H, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J. 2014;55:533\u20138.","journal-title":"Int Heart J"},{"key":"2325_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13730-020-00518-1","volume":"10","author":"K Kakeshita","year":"2021","unstructured":"Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Expression of aquaporin-2 in the collecting duct and responses to tolvaptan. CEN Case Rep. 2021;10:69\u201373.","journal-title":"CEN Case Rep"},{"key":"2325_CR10","doi-asserted-by":"publisher","first-page":"12950","DOI":"10.3390\/ijms222312950","volume":"22","author":"Y Noda","year":"2021","unstructured":"Noda Y, Sasaki S. Updates and perspectives on aquaporin-2 and water balance disorders. Int J Mol Sci. 2021;22:12950.","journal-title":"Int J Mol Sci"},{"key":"2325_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s10157-022-02220-1","volume":"26","author":"K Kakeshita","year":"2022","unstructured":"Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease. Clin Exp Nephrol. 2022;26:788\u201396.","journal-title":"Clin Exp Nephrol"},{"key":"2325_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2325_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1172\/JCI108831","volume":"60","author":"AE Broadus","year":"1977","unstructured":"Broadus AE, Mahaffey JE, Bartter FC, Neer RM. Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. J Clin Invest. 1977;60:771\u201383.","journal-title":"J Clin Invest"},{"key":"2325_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients - association between non-responders and chronic kidney disease. Circ J. 2013;77:397\u2013404.","journal-title":"Circ J"},{"key":"2325_CR15","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240\u20139.","journal-title":"Circ J"},{"key":"2325_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000381859","volume":"130","author":"H Iwatani","year":"2015","unstructured":"Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, et al. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron. 2015;130:8\u201312.","journal-title":"Nephron"},{"key":"2325_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","volume":"21","author":"M Katsumata","year":"2017","unstructured":"Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol. 2017;21:858\u201365.","journal-title":"Clin Exp Nephrol"},{"key":"2325_CR18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s11255-019-02180-8","volume":"51","author":"T Masuda","year":"2019","unstructured":"Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, et al. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. Int Urol Nephrol. 2019;51:1623\u20139.","journal-title":"Int Urol Nephrol"},{"key":"2325_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00380-017-1066-4","volume":"33","author":"K Takagi","year":"2018","unstructured":"Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, et al. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart Vessels. 2018;33:413\u201320.","journal-title":"Heart Vessels"},{"key":"2325_CR20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s10157-022-02264-3","volume":"26","author":"K Kakeshita","year":"2022","unstructured":"Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Prognostic impact of urine cyclic AMP levels in patients with chronic kidney disease. Clin Exp Nephrol. 2022;26:1194\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2325_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0272-2712(18)30465-7","volume":"13","author":"BB Davis","year":"1993","unstructured":"Davis BB, Zenser TV. Evaluation of renal concentrating and diluting ability. Clin Lab Med. 1993;13:131\u20134.","journal-title":"Clin Lab Med"},{"key":"2325_CR22","first-page":"26","volume":"11","author":"EB Pedersen","year":"2010","unstructured":"Pedersen EB, Thomsen IM, Lauridsen TG. Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study BMC Nephrol. 2010;11:26.","journal-title":"A case control study BMC Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02325-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T15:02:25Z","timestamp":1681484545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02325-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02325-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by our institutional review board (IRB approval number R2015144) and carried out following the Declaration of Helsinki. Clinical trial registration: UMIN000022422.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients before the inclusion in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}